May 15, 2013

Foundation Medicine to Present Clinical Data on its FoundationOne™ Cancer Genomic Profile at the 2013 ASCO Annual Meeting

CAMBRIDGE, Mass., May 15, 2013 - Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic diagnostic testing and analysis to routine clinical care, today announced that 12 abstracts highlighting the company's progress in clinical cancer genome sequencing will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2013 taking place May 31-June 4, 2013 in Chicago.

"As clinical adoption of our solid tumor assay, FoundationOne™, continues to increase, we are generating a large body of evidence suggesting that a comprehensive genomic profile may provide clinically actionable information for many patients with cancer," said Michael J. Pellini, M.D., president and chief executive officer, Foundation Medicine. "These data include novel findings across many tumor types and for many genomic targets. The 2013 ASCO meeting will be an exciting venue to share and discuss new discoveries in cancer genomics with the broader oncology community."

The schedule for presentations by Foundation Medicine and/or its collaborators is as follows:

Date & Time: Saturday, June 1, 2013 from 8:00 a.m. - 12:00 p.m. CT
Title: Frequent LOH of CYP2D6 in ER+ breast cancer determined by next-generation sequencing (NGS)
Abstract: 534
Session: Poster Discussion Session: Breast Cancer - HER2/ER
Location: E450b
Presenter: Mark J. Ratain, M.D.
Research in collaboration with The University of Chicago Comprehensive Cancer Center

Date & Time: Saturday, June 1, 2013 from 8:00 a.m. - 12:00 p.m. CT
Title: Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions
Abstract: 10513
Session: Poster Discussion Session: Sarcoma
Location: S102
Presenter: Christine M. Lovly, M.D., Ph.D.
Research in collaboration with Vanderbilt-Ingram Cancer Center

Date & Time: Saturday, June 1, 2013 from 1:15 - 5:00 p.m. CT
Title: Next generation sequencing (NGS) in patients with advanced metastatic breast cancer: identification of molecular alterations and analysis of associations with treatment on Phase I studies at MD Anderson Cancer Center
Abstract: 1051
Session: General Poster Session: Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Location: S Hall A2
Presenter: Jennifer J. Wheler, M.D.
Research in collaboration with MD Anderson Cancer Center

Date & Time: Saturday, June 1, 2013 from 1:15 - 5:00 p.m. CT
Title: Targeted next-generation sequencing of sarcomas for identification of therapeutic targets
Abstract: 10577
Session: General Poster Session: Sarcoma
Location: S Hall A2
Presenter: Vinod Ravi, M.D.
Research in collaboration with MD Anderson Cancer Center

Date & Time: Saturday, June 1, 2013 from 2:00 - 2:15 p.m. CT
Title: Next generation sequencing of genomic and cDNA identifies a high frequency of kinase fusions involving ROS1, ALK, RET, NTRK1, and BRAF in Spitz tumors
Abstract: 9002
Session: Oral Abstract Session: Melanoma/Skin Cancers
Location: 5406
Presenter: Boris Bastian, M.D., Ph.D., University of California, San Francisco

Date & Time: Sunday, June 2, 2013 from 8:00 - 8:15 a.m. CT
Title: An analysis of ERBB2 alterations (amplifications and mutations) found by next generation sequencing (NGS) in 2000+ consecutive solid tumor (ST) patients
Abstract: 11000
Session: Oral Abstract Session: Tumor Biology
Location: E354b
Presenter: Massimo Cristofanilli, M.D., F.A.C.P., Thomas Jefferson University-Kimmel Cancer Center

Date & Time: Sunday, June 2, 2013 from 8:00 a.m. - 12:00 p.m. CT
Title: Clinical next generation sequencing (NGS) to reveal high frequency of alterations to guide targeted therapy in lung cancer patients
Abstract: 8020
Session: Poster Discussion Session: Lung Cancer - Non-small Cell Metastatic
Location: E450b
Presenter: Siraj M. Ali, M.D., Ph.D.

Date & Time: Sunday, June 2, 2013 from 8:00 a.m. - 12:00 p.m. CT
Title: NTRK1 gene fusions represent a novel oncogene target in lung cancer
Abstract: 8023
Session: Poster Discussion Session
Location: E450b
Presenter: Robert C. Doebele, M.D., Ph.D.
Research in collaboration with the University of Colorado Denver School of Medicine

Date & Time: Monday, June 3, 2013 from 8:00 a.m. - 12:00 p.m. CT
Title: Use of next-generation sequencing (NGS) to identify actionable genomic alterations (GA) in diverse solid tumor types: The Foundation Medicine (FMI) experience with 2,200+ clinical samples
Abstract: 11020
Session: Poster Discussion Session: Tumor Biology
Location: S102
Presenter: Vincent A. Miller, M.D.

Date & Time: Monday, June 3, 2013 from 1:15 - 5:15 p.m. CT
Title: Use of the FoundationOne next-generation sequencing (NGS) assay to detect actionable alterations leading to clinical benefit of targeted therapies for relapsed and refractory breast cancer
Abstract: 1009
Session: Poster Discussion Session: Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Location: S102
Presenter: Jeffrey S. Ross, M.D.

Date & Time: Monday, June 3, 2013 from 1:15 - 5:00 p.m. CT
Title: Clinical next generation sequencing (NGS) of fine needle aspiration (FNA) biopsies in non-small cell lung (NSCLC) and pancreatic cancers
Abstract: 11100
Session: General Poster Session: Tumor Biology
Location: S Hall A2
Presenter: Matthew J. Hawryluk, Ph.D.

Date & Time: Monday, June 3, 2013 from 1:15 - 5:00 p.m. CT
Title: Frequency of MET amplification determined by comprehensive next generation sequencing (NGS) in multiple solid tumors and implications for use of MET inhibitors
Abstract: 11068
Session: General Poster Session: Tumor Biology
Location: S Hall A2
Presenter: Norma A. Palma, Ph.D.

About FoundationOne™
FoundationOne is a fully informative genomic profile that complements traditional cancer decision tools and often expands treatment options by matching each patient with targeted therapies that may be relevant to the molecular changes in their tumor. Using next-generation sequencing, FoundationOne interrogates all genes somatically altered in human cancers that are validated targets for therapy or unambiguous drivers of oncogenesis based on current knowledge. It reveals all classes of genomic alterations including base substitutions, insertions, deletions, copy number alterations and select rearrangements. Each patient's genomic profile is reported to the physician matched with targeted therapies and clinical trials that may be relevant based on the molecular blueprint of their tumor. Results are supported by the latest scientific and medical evidence.

FoundationOne has been optimized to fit easily into the clinical workflow of a practicing oncologist. It is available for all solid tumors and clinical grade results can be obtained from as little as 50ng of DNA obtained from formalin-fixed, paraffin-embedded tumor tissue samples. FoundationOne is a laboratory-developed test performed at Foundation Medicine's CLIA-certified facility and is currently available for all solid tumor types. Please visit www.FoundationOne.com for more information.

About Foundation Medicine

Foundation Medicine® is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's initial clinical assay, FoundationOne™, is a fully informative genomic profile to identify a patient's individual molecular alterations and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

Contact:
Dan Budwick
Pure Communications, Inc.
(973) 271-6085